ALK and non-small cell lung carcinoma: The objective of this study was to evaluate the clinical safety and efficacy of ceritinib in Japanese patients with ALK+ unresectable advanced/recurrent NSCLC and also to identify any safety and efficacy issues in paediatric, elderly and pregnant patients and in patients with renal/hepatic impairment, interstitial lung disease or heart disease, if they were enrolled in the study.